Can an adult safely take 70 mg of Vyvanse (lisdexamfetamine)?

Can an Adult Take 70 mg of Vyvanse?

Yes, 70 mg of Vyvanse (lisdexamfetamine) is an FDA-approved dose for adults and represents the maximum recommended daily dose for ADHD treatment. 1

FDA-Approved Dosing for Adults

• The FDA label explicitly includes 70 mg as an approved dose for adults with ADHD, with clinical trials demonstrating safety and efficacy at this dose level. 1
• Asian clinical guidelines from Japan specify 70 mg as the maximum daily dose for lisdexamfetamine in adults. 2
• Multiple controlled trials in adults used 70 mg as the highest dose tier, showing significant improvements in ADHD symptoms with acceptable tolerability. 3, 4

Clinical Efficacy at 70 mg

• In a 4-week placebo-controlled trial of 420 adults, 70 mg lisdexamfetamine reduced ADHD Rating Scale scores by 18.6 points compared to 8.2 points with placebo (p < 0.0001). 3
• 61% of adults taking 70 mg achieved Clinical Global Impressions-Improvement scores ≤2 (much or very much improved) versus 29% on placebo. 3
• Symptom improvements were sustained for up to 12 months in open-label extension studies at doses up to 70 mg. 5
• Efficacy extends to 14 hours post-dose, making 70 mg suitable for managing symptoms throughout the workday and into evening hours. 4

Safety Profile at 70 mg

Common adverse effects at 70 mg include:

• Decreased appetite (27-34% vs 2-3% placebo) 1
• Insomnia (13-27% vs 4-8% placebo) 1
• Dry mouth (26-36% vs 1-7% placebo) 1
• Weight loss (mean 4.3 pounds after 4 weeks) 1

Cardiovascular monitoring is mandatory:

• Pulse increased by a mean of 5.2 bpm at 70 mg compared to baseline (p < 0.05 vs placebo). 6
• Blood pressure changes were not statistically significant in controlled trials, though individual monitoring remains essential. 6
• Check blood pressure and pulse at baseline and with each dose adjustment, then quarterly during stable maintenance therapy. 7

Critical Dosing Context

The 70 mg dose should only be reached through proper titration:

• Start at 30 mg daily in the morning, then increase by 10-20 mg increments at weekly intervals based on response and tolerability. 8
• Do not skip titration steps—forced-dose escalation protocols in clinical trials still began at 30 mg. 3

When 70 mg is insufficient:

• Do not exceed 70 mg of lisdexamfetamine—the FDA label does not support higher doses. 1
• Consider switching to methylphenidate-based stimulants rather than exceeding maximum amphetamine doses, as approximately 90% of patients respond when both stimulant classes are tried sequentially. 7
• Reassess for comorbid conditions (anxiety, depression, sleep disorders) that may mimic treatment-resistant ADHD. 7

Contraindications and Red Flags

Do not use 70 mg (or any dose) if:

• The patient is taking or has taken MAO inhibitors within 14 days—this combination can cause hypertensive crisis. 1
• There is known hypersensitivity to amphetamine products. 1
• Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, or hyperthyroidism is present. 1

Discontinue and evaluate if:

• Pulse outliers (≥100 bpm) occur—seen in 3.3-8.5% of patients on lisdexamfetamine. 6
• New psychiatric symptoms emerge (psychosis, mania, aggression). 1
• Cardiovascular symptoms develop (chest pain, unexplained syncope, palpitations). 1

Practical Considerations

• Take once daily in the morning—do not administer in the afternoon or evening to minimize insomnia. 8
• Food does not significantly affect absorption, though it delays time to peak concentration by approximately 1 hour. 1
• The capsule may be opened and mixed with water or orange juice if swallowing is difficult—bioavailability remains equivalent. 1
• Plasma half-life of dextroamphetamine (the active metabolite) is 10-11.3 hours in adults, supporting once-daily dosing. 1

Special Population Guidance

For patients with cardiovascular risk factors:

• Exclude patients with structural cardiac abnormalities or serious heart rhythm disorders before initiating any stimulant, including 70 mg lisdexamfetamine. 1
• Obtain baseline ECG if there is personal or family history of cardiac disease—though routine ECG screening is not required in healthy adults. 6

For patients with substance use concerns:

• Lisdexamfetamine is a Schedule II controlled substance with potential for abuse and dependence. 1
• The prodrug design provides lower abuse liability compared to immediate-release amphetamines, as lisdexamfetamine must be enzymatically converted to active dextroamphetamine. 1, 9